New research in BMJ Open suggests a promising link between GLP-1 receptor agonists – commonly used to manage type 2 diabetes and obesity – and reduced hospitalisations for alcohol-related illnesses. The study, which drew on vast amounts of routine healthcare data, simulated a clinical trial comparing these medications with other treatments for similar conditions.
According to Professor Ashwin Dhanda, expert in liver medicine at the University of Plymouth, the findings support the notion that GLP-1 receptor agonists can reduce alcohol consumption and associated health problems. Crucially, he highlights a significant drop in risk of hospitalisation related to alcohol within the first year of treatment with these medications.
While Prof Dhanda praises the study's robust design, including its large sample size and careful matching of comparison groups, he also notes some limitations. He points out that the participants may not be representative of all individuals struggling with alcohol use disorder – particularly those who don't regularly access healthcare services. Moreover, while an association between newer GLP-1 RAs and reduced hospital visits was observed, this study cannot definitively prove their effectiveness in treating alcohol use disorder or rule out potential side effects.
Dr Marie Spreckley, a researcher at the University of Cambridge specialising in weight management, also acknowledges the strengths of the study's methods. However, she cautions that observational studies like this one can only suggest associations and not establish direct cause-and-effect relationships. Factors such as severity of alcohol use disorder or socioeconomic circumstances might not have been fully taken into account, leaving some uncertainty.
Prof Dhanda, Dr Spreckley, and Professor Colin Angus – an expert in alcohol policy at Sheffield University Addictions Research Group – all agree that well-designed clinical trials are essential to confirm the safety and effectiveness of GLP-1 receptor agonists for treating alcohol use disorder. They highlight the need for more representative participant groups and stress that existing disparities in access to these treatments could skew the study's findings.
Prof Angus also notes the high cost of newer GLP-1 medications, which may exacerbate access issues and influence the results observed in this study.